Oruka Therapeutics Insider Arjun Agarwal Sells Shares
Arjun Agarwal sold 395 shares of Oruka Therapeutics as part of a planned sale.
Key Points
- Arjun Agarwal, Senior VP of Finance at Oruka Therapeutics, sold 395 shares valued at $27,527.55 on June 15, 2026.
- Oruka Therapeutics trades on NasdaqGM with a market cap of $4.22 billion and a 52-week range of $10.77 to $91.00.
- Analysts maintain strong buy ratings, with BTIG setting a price target of $151 as of May 14, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, Arjun Agarwal, the Senior Vice President of Finance at Oruka Therapeutics, Inc. (NasdaqGM: ORKA), sold 395 shares of the company's stock. This planned transaction was executed at an average price of $69.69 per share, totaling $27,527.55.
Insider Buying and Selling at Oruka Therapeutics, Inc.
Arjun Agarwal wasn't the only insider trading shares of Oruka Therapeutics. On the same day, Joana Goncalves, the Chief Medical Officer, bought 7,000 shares at $7.32 each. She also sold 3,500 shares, though the transaction price wasn't disclosed. Additionally, Laura Lee Sandler, the Chief Operating Officer, sold 600 shares at $69.69, and Paul Quinlan, General Counsel, sold 733 shares at the same price. These transactions were not part of pre-arranged plans.
Oruka Therapeutics, Inc. Stock Down 24.5%
Shares of Oruka Therapeutics, Inc. traded near $69.89, with the company boasting a market cap of $4.22 billion. Currently, the stock has a forward P/E ratio that is not meaningful due to negative earnings. The stock's 52-week range is $10.77 to $91.00, and it has 50-day and 200-day moving averages of $63.70 and $37.60, respectively. With a current ratio of 23.76 and a debt-to-equity ratio of 0.37, Oruka appears financially stable.
$ORKA stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On May 14, 2026, BTIG reiterated its buy rating on Oruka Therapeutics with a price target of $151. Other analysts, including HC Wainwright & Co. and UBS, have maintained buy ratings with targets of $120 and $100, respectively. The consensus among 12 analysts is a strong buy, with a mean target price of $142.17.
About Oruka Therapeutics
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Menlo Park, California. It focuses on developing novel monoclonal antibody therapies for psoriasis and other inflammatory conditions. The company's leading products include ORKA-001 and ORKA-002, both in phase 2 trials for various conditions. Oruka is led by CEO Dr. Lawrence Otto Klein and employs 68 people.
Bottom Line
Arjun Agarwal's recent share sale at Oruka Therapeutics was part of a planned transaction, reflecting typical insider activity. Oruka remains a company of interest due to its significant market presence and ongoing clinical trials. Investors often track insider sales to gauge executive sentiment, but these transactions are not definitive indicators of future stock performance.
Get Oruka Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ORKA, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.